Literature DB >> 1914759

Comparative tolerability profile of omeprazole in clinical trials.

T J Simon1, D C Bradstreet.   

Abstract

The tolerability of omeprazole was compared to control agents in 68 clinical studies that enrolled a total of 4846 patients, of whom 3096 received omeprazole. The incidence of adverse experiences was independent of omeprazole dose administered, the age of the patients, and the disease treated (duodenal ulcer or endoscopically verified gastroesophageal reflux disease). The most common clinical adverse experiences were headache, diarrhea, abdominal pain, and nausea. The most common laboratory adverse experiences were elevated aspartate aminotransferase and elevated alanine aminotransferase. Omeprazole was well tolerated, and the incidence of clinical and laboratory adverse experiences was similar in patients receiving omeprazole, placebo, cimetidine, or ranitidine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1914759     DOI: 10.1007/bf01296803

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  Effect of omeprazole and cimetidine on duodenal ulcer. A double-blind comparative trial.

Authors:  K Lauritsen; S J Rune; P Bytzer; H Kelbaek; K G Jensen; J Rask-Madsen; F Bendtsen; J Linde; M Højlund; H H Andersen
Journal:  N Engl J Med       Date:  1985-04-11       Impact factor: 91.245

2.  Double blind comparative study of omeprazole 10 mg and 30 mg daily for healing duodenal ulcers.

Authors:  P J Prichard; D Rubinstein; D B Jones; F J Dudley; R A Smallwood; W J Louis; N D Yeomans
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-23

3.  [Comparative efficacy of omeprazole and cimetidine in the treatment of duodenal ulcer in the acute stage. A French multicenter, controlled therapeutic trial].

Authors:  M A Bigard; J P Isal; J P Galmiche; F Ebrard; J P Bader
Journal:  Gastroenterol Clin Biol       Date:  1987-11

4.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

5.  Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study.

Authors:  S Sandmark; R Carlsson; O Fausa; L Lundell
Journal:  Scand J Gastroenterol       Date:  1988-06       Impact factor: 2.423

6.  Double-blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis.

Authors:  E C Klinkenberg-Knol; J M Jansen; H P Festen; S G Meuwissen; C B Lamers
Journal:  Lancet       Date:  1987-02-14       Impact factor: 79.321

7.  Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis.

Authors:  G Vantrappen; L Rutgeerts; P Schurmans; J L Coenegrachts
Journal:  Dig Dis Sci       Date:  1988-05       Impact factor: 3.199

8.  Rapid healing of duodenal ulcers with omeprazole: double-blind dose-comparative trial.

Authors:  S Gustavsson; H O Adami; L Lööf; A Nyberg; O Nyrén
Journal:  Lancet       Date:  1983-07-16       Impact factor: 79.321

9.  Maintenance treatment with cimetidine in peptic ulcer disease for up to 4 years.

Authors:  A Walan; G Bianchi-Porro; E Hentschel; K D Bardhan; M Delattre
Journal:  Scand J Gastroenterol       Date:  1987-05       Impact factor: 2.423

10.  The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms.

Authors:  S Dahlgren; L Domellöf; M Hradsky; C Norryd; J Brunkwall; G Svensson; J O Svensson; J Karlsson; U Knutson; T Gasslander
Journal:  Aliment Pharmacol Ther       Date:  1988-12       Impact factor: 8.171

View more
  3 in total

Review 1.  Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.

Authors:  L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

Review 2.  Single-isomer drugs: true therapeutic advances.

Authors:  Tommy Andersson
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.